Estrasorb is topical emulsion containing oestrogen. oestrogen may be a variety of steroid hormone, a feminineinternal secretion that regulates several processes within the body.

Estrasorb is employed to once biological time to scale back moderate to severe hot flashes. The ovaries commonlystop creating estrogens once a lady is between forty five to fifty five years previous. once the steroid hormonelevels begin dropping, some girls develop terribly uncomfortable symptoms, like feelings of heat within the face, neck, and chest, or unforeseen sturdy feelings of warmth and sweating (“hot flashes” or “hot flushes”). In some girls, the symptoms square measure gentle, and that they won’t want estrogens. In alternative girls, symptoms will beadditional severe.

Submit your review

Create your own review

Average rating:  
 0 reviews
  • Divigel, Elestrin Pump, Estrasorb, EstroGel Pump, Evamist
  • Get emergency medical help if you have signs of an allergic reaction to Estrasorb: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

    Stop using Estrasorb and call your doctor at once if you have:

    abnormal vaginal bleeding;
    a lump in your breast;
    confusion, problems with memory or concentration;
    heart attack symptoms--chest pain or pressure, pain spreading to your jaw or shoulder, nausea, sweating;
    liver problems--nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
    signs of a stroke--sudden numbness or weakness (especially on one side of the body), sudden severe headache, slurred speech, problems with vision or balance;
    signs of a blood clot in the lung--chest pain, sudden cough, wheezing, rapid breathing, coughing up blood; or
    signs of a blood clot in your leg--pain, swelling, warmth, or redness in one or both legs.
    Topical estradiol is absorbed through the skin of a child who comes into contact with this medicine. Call your doctor if a child who has close contact with you develops swollen nipples or enlarged breasts.

    Common Estrasorb side effects may include:

    breast pain;
    vaginal itching or discharge, changes in your menstrual periods, light vaginal bleeding or spotting;
    thinning scalp hair; or
    nausea, vomiting, bloating, stomach cramps.
  • Usual Adult Dose for Postmenopausal Symptoms Oral: 0.45 mg to 2 mg orally once a day. Parenteral: 1 to 5 mg of estradiol cypionate IM every 3 to 4 weeks or 10 to 20 mg of estradiol valerate IM every 4 weeks. Vaginal Ring: 0.05 mg/day or 0.1 mg/day vaginal ring. The ring should remain in place for 3 months and then be replaced by a new ring if therapy is to continue. Topical: 0.025 to 0.1 mg/day (transdermal film) applied topically 1 or 2 times a week. Application sites vary according to manufacturer formulation and include the lower abdomen, upper thigh, buttocks, or upper arm. Systems should not be applied to the breasts. 0.05 mg/day (2 foil pouches of transdermal emulsion) applied topically to both legs each morning. 0.25 mg unit dose packet (0.1% transdermal gel) applied topically once daily to the upper right or left thigh at the same time daily. 1.25 g (one spray) EstroGel (0.75 mg/1.25 gm - 0.06% transdermal gel) applied topically to the arms at the same time daily. 1.53 mg (one spray) Evamist (1.53 mg/spray transdermal spray) applied topically to the forearm at the same time daily. 0.87 g (one spray) Elestrin (0.52 mg/1.087 g - 0.06% transdermal gel) applied topically to the upper arm at the same time daily. Women currently on oral estrogen therapy and changing to a transdermal estradiol system should initiate transdermal therapy 1 week following discontinuation of oral estrogens (sooner if menopausal symptoms reappear). Changes between transdermal systems may be initiated without interruption of therapy. In general, the duration of hormone therapy for the treatment of postmenopausal symptoms should be limited. Treatment for one to five years is generally sufficient. However, long-term therapy (for the treatment/prophylaxis of osteoporosis and for risk reduction of cardiovascular disease) may be considered during the time in which the patient is being treated for postmenopausal symptoms. Because of the potential increased risks of cardiovascular events, breast cancer and venous thromboembolic events, use should be limited to the shortest duration consistent with treatment goals and risks for the individual woman, and should be periodically reevaluated. When used solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.